Drug Type Monoclonal antibody |
Synonyms 2141 V11, 2141-V11 |
Target |
Action agonists |
Mechanism CD40 agonists(Tumor necrosis factor receptor superfamily member 5 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 2 | United States | 28 Mar 2024 | |
Glioblastoma Multiforme | Phase 2 | United States | 06 Sep 2023 | |
Glioblastoma, IDH-Wildtype | Phase 1 | United States | 17 Mar 2025 | |
Recurrent Glioblastoma | Phase 1 | United States | 17 Mar 2025 | |
Recurrent Malignant Glioma | Phase 1 | United States | 09 Jul 2021 |
Phase 2 | Recurrent Glioblastoma IDH wild-type | 18 | D2C7-IT+2141-V11 via CED | utqantsoqn(odssarqmyy) = grade 1 injection site reaction (n=16) teknlwgsol (vljsvnbxap ) View more | Positive | 11 Nov 2024 | |
Phase 1 | - | enwjitcuyj(vuelfqntaz) = bogavhqxcc wxwhhtqlgf (ridowgjeyf ) View more | Positive | 03 Jun 2024 | |||
NCT04547777 (ASCO2022) Manual | Phase 1 | 8 | ezcgysnvme(xpuyovrccl) = oqulffrvlk pctoevodig (edknzrsufw ) | Positive | 02 Jun 2022 |